BioStock: Ultimovacs poised for major clinical transition

With its latest quarterly report, Norwegian immuno-oncology company Ultimovacs highlights the continued progress with its broad clinical programme evaluating universal cancer vaccine UV1. Patient recruitment is in full swing within all five of the company’s phase II trials, and encouraging survival data from their phase I UV1/pembrolizumab combination study in malignant melanoma were recently announced. With solid finances at its back, Ultimovacs is in a good position to reach significant clinical development milestones next year. BioStock spoke with CEO Carlos de Sousa to get his take.

Read the interview with Carlos de Sousa at biostock.se:

Ultimovacs poised for major clinical transition - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/